Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America.
Department of Immunobiology, Yale School of Medicine, New Haven, Connecticut, United States of America.
PLoS Pathog. 2023 Jul 6;19(7):e1011351. doi: 10.1371/journal.ppat.1011351. eCollection 2023 Jul.
Identification of host determinants of coronavirus infection informs mechanisms of pathogenesis and may provide novel therapeutic targets. Here, we demonstrate that the histone demethylase KDM6A promotes infection of diverse coronaviruses, including SARS-CoV, SARS-CoV-2, MERS-CoV and mouse hepatitis virus (MHV) in a demethylase activity-independent manner. Mechanistic studies reveal that KDM6A promotes viral entry by regulating expression of multiple coronavirus receptors, including ACE2, DPP4 and Ceacam1. Importantly, the TPR domain of KDM6A is required for recruitment of the histone methyltransferase KMT2D and histone deacetylase p300. Together this KDM6A-KMT2D-p300 complex localizes to the proximal and distal enhancers of ACE2 and regulates receptor expression. Notably, small molecule inhibition of p300 catalytic activity abrogates ACE2 and DPP4 expression and confers resistance to all major SARS-CoV-2 variants and MERS-CoV in primary human airway and intestinal epithelial cells. These data highlight the role for KDM6A-KMT2D-p300 complex activities in conferring diverse coronaviruses susceptibility and reveal a potential pan-coronavirus therapeutic target to combat current and emerging coronaviruses. One Sentence Summary: The KDM6A/KMT2D/EP300 axis promotes expression of multiple viral receptors and represents a potential drug target for diverse coronaviruses.
鉴定冠状病毒感染的宿主决定因素可以阐明发病机制,并为提供新的治疗靶点。在这里,我们证明组蛋白去甲基化酶 KDM6A 以去甲基化酶活性非依赖的方式促进多种冠状病毒的感染,包括 SARS-CoV、SARS-CoV-2、MERS-CoV 和鼠肝炎病毒 (MHV)。机制研究表明,KDM6A 通过调节多种冠状病毒受体的表达,包括 ACE2、DPP4 和 Ceacam1,来促进病毒进入。重要的是,KDM6A 的 TPR 结构域是募集组蛋白甲基转移酶 KMT2D 和组蛋白去乙酰化酶 p300 的必需条件。该 KDM6A-KMT2D-p300 复合物共同定位于 ACE2 的近端和远端增强子,并调节受体表达。值得注意的是,p300 催化活性的小分子抑制消除了 ACE2 和 DPP4 的表达,并赋予了原代人呼吸道和肠道上皮细胞对所有主要 SARS-CoV-2 变体和 MERS-CoV 的抗性。这些数据强调了 KDM6A-KMT2D-p300 复合物活性在赋予多种冠状病毒易感性方面的作用,并揭示了一个潜在的泛冠状病毒治疗靶点,以对抗当前和新兴的冠状病毒。一句话总结:KDM6A/KMT2D/EP300 轴促进多种病毒受体的表达,是多种冠状病毒的潜在药物靶点。